Completed

Early Whole Blood in Patients Requiring Transfusion After Major Trauma

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Transfusion of blood products

Biological
Who is being recruted

Accidental Injuries+5

+ Cardiovascular Diseases

+ Hematologic Diseases

From 18 to 100 Years
See all eligibility criteria
How is the trial designed

Treatment Study

Phase 4
Interventional
Study Start: May 2011
See protocol details

Summary

Principal SponsorThe University of Texas Health Science Center, Houston
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: May 1, 2011

Actual date on which the first participant was enrolled.

Background: The acquired coagulopathy of trauma is responsible for a large percentage of early deaths in civilian trauma practice and is a major cause of battlefield mortality. Widespread recognition has provided a rationale for fundamental changes in the initial management of severely injured patients through prevention of hypothermia, damage control surgery, massive transfusion protocols and early triage to intensive care units for optimized resuscitation. Despite these major advances, hemorrhage remains a leading cause of early death in both civilian trauma and military combat casualty care. However, it is unclear how early whole blood will affect coagulopathy in this cohort of patients as compared to the current standard of care. Objective/Hypothesis: The proposal will assess if patients who require massive transfusion can be accurately predicted early after emergency department arrival and assess if the use of stored whole blood during initial resuscitation will reduce transfusion needs compared to transfusion with component therapy and thus improve outcome. Study Design: As a first step in testing this hypothesis, we will test commonly utilized point of care analysis devices and determine their reliability in predicting transfusion requirements in severely injured trauma patients within 20 minutes after arrival in the emergency department. Furthermore, we will prospectively randomize severely injured patients who require a blood transfusion to receive either stored whole blood and pooled platelets or component therapy (packed red blood cells, fresh frozen plasma, and platelets, our current standard of care) and compare the ability of stored whole blood to reduce transfusion needs and improve clinical outcomes. Relevance: Severe uncontrollable coagulopathy in major trauma patients continues to be a major determinant of trauma mortalities. The proposed effort aims to provide an early, coagulopathy-based prediction model to identify patients at risk for massive transfusion. Moreover, our proposal intends to evaluate early stored whole blood transfusion in this at risk patient population and determine stored whole blood's ability to prevent or control severe coagulopathy compared to standard transfusion care.

Official TitleEarly Whole Blood in Patients Requiring Transfusion After Major Trauma
NCT01227005
Principal SponsorThe University of Texas Health Science Center, Houston
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

107 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.


Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 18 to 100 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Accidental InjuriesCardiovascular DiseasesHematologic DiseasesHemic and Lymphatic DiseasesHemorrhagic DisordersVascular DiseasesWounds and InjuriesHemostatic Disorders

Criteria

Inclusion Criteria: 1. 18 years of age or older. 2. Meet Code 3 status; Code 3 is determined by the following criteria (Patients must meet at least one of the following physiologic and/or anatomic criteria): * Physiologic criteria indicating high risk or life threatening injuries * GCS \<10 (Glasgow Coma Scale) * SBP \<90 (Systolic blood pressure) * RR \<10 or \>29 (Respiratory rate) * HR \>120 (Heart rate) * intubated * Base Deficit \> 6 * Anatomic criteria indicating high risk or life threatening injuries * Any penetrating injury to torso, groin, or neck * Amputation proximal to the ankle or wrist * Uncontrolled external hemorrhage * Two or more long bone fractures * Pelvic fracture * Paraplegia or quadriplegia * Combination trauma with burns ≥ 20% BSA (body surface area) 3. Demonstrate evidence of blood loss due to injury, requiring transfusion in the ED. Exclusion Criteria: 1. Death thought to be imminent, suggesting a futile resuscitation effort 2. Known or assumed religious objection to blood products 3. Do not resuscitate order in place 4. Women who present to the ED who are obviously pregnant. 5. Patients who appear to the ED wearing the -opt-out‖ bracelet provided at the community consultation.

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

2 intervention groups are designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Active Comparator
Red blood cells, plasma, platelets

Group II

Active Comparator
Whole Blood plus pooled platelets

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Suspended

Memorial Hermann Hospital - Texas Medical Center

Houston, United StatesOpen Memorial Hermann Hospital - Texas Medical Center in Google Maps
CompletedOne Study Center